Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis
| Autor: | Aramesh Saremi, Francisco J. Tinahones, Pablo Aschner, Adam G. Tabak, Juris J. Meier, Peter Stella, Carol Wysham, John E Anderson, Minzhi Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Hypoglycemia Gastroenterology iGlarLixi 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus Internal medicine Internal Medicine medicine Original Research Insulin glargine business.industry Weight change Weight control nutritional and metabolic diseases medicine.disease Regimen chemistry Insulin therapy Glycated hemoglobin business medicine.drug |
| Zdroj: | Diabetes Therapy |
| ISSN: | 1869-6961 1869-6953 |
| Popis: | Introduction Basal-bolus (BB) regimens are generally used to intensify basal insulin therapy in patients with type 2 diabetes (T2D) not meeting glycemic targets. However, drawbacks include multiple injection burden and risk of weight gain and hypoglycemia. A once-daily titratable fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) may provide a simple, well-tolerated, and efficacious alternative. We compared these treatments in a post hoc propensity score matched analysis using randomized trial data. Methods From the LixiLan-L study, 195 patients who had been randomized to iGlarLixi were matched for age, sex, race, T2D duration, baseline body mass index, glycated hemoglobin (HbA1c), fasting plasma glucose, insulin dose, and metformin use to 195 patients who had been randomized to a BB regimen in the GetGoal Duo-2 trial. Results At study end, estimated treatment differences for reduction in HbA1c and weight change, and ratio of hypoglycemia events per patient-year (BB vs iGlarLixi) were − 0.28% (standard error 0.08, P = 0.0002), − 1.32 kg (standard error 0.30, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink